The CHMP has granted accelerated assessment to CHIKV VLP chikungunya vaccine, the MAA submission of which to the EMA is anticipated in H1’24 based on two P-III studies
One of the P-III trial of CHIKV VLP (IM) vs PBO in healthy subjects (n=3,254; 12yrs.-64yrs.), depicted production of chikungunya neutralizing Ab in 98% of individuals after 22 days while in 47% & 97% of individuals after 8 & 15 days of vaccination respectively. Seroprotective Ab were found in 86% individuals after 6mos. of vaccination
Another P-III study in healthy subjects (n=413; ≥65yrs.) demonstrated neutralizing Ab in 87% of subjects after 22 days of single vaccination. Seroprotective Ab were found in 82% of subjects at day 15
Ref: Bavarian Nordic | Image: Bavarian Nordic
Related News:- Bavarian Nordic to Acquire Emergent BioSolutions’ Vivotif, Vaxchora and an Under Developed Chikungunya Vaccine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
